SMA Research Platform

Evidence graph for Spinal Muscular Atrophy

Biology-first target discovery
Christian Fischer / Bryzant Labs
13,282Targets
453Trials
84Drugs
7Datasets
42,694Sources
48,101Claims
55,096Evidence
29,646Hypotheses
DRUGphase2antibody

taldefgrobep alfa

Brand names: BHV-2000

Mechanism

Anti-myostatin antibody. Inhibits myostatin to promote muscle growth and prevent atrophy.

Related claims (1)

TypePredicateConfSource
drug targetTaldefgrobep alfa selectively binds to myostatin and competitively inhibits other ligands that signal through the activin II receptor.59%39408601

Off-Target Findings (0)

No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.

Login → Command Center